GuidelineJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.
Guideline in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and meta-aggregation.The journal of pathology. Clinical research · 2021Pooled it
- Article
- Recommendations for Tissue Microarray Construction and Quality Assurance.Applied immunohistochemistry & molecular morphology : AIMM · 2020Article
- Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.Head & neck · 2017Article
- Sampling strategies to capture single-cell heterogeneity.Nature methods · 2017Article
- Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers.Oncotarget · 2017Article
- Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).Journal of ovarian research · 2017Article
- A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression.Scientific reports · 2016Article
- PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).NPJ breast cancer · 2016Article
- TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.British journal of cancer · 2015Article
- Application of molecular technologies for phosphoproteomic analysis of clinical samples.Oncogene · 2015Review
- Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma.Virchows Archiv : an international journal of pathology · 2014Article
- A 'waterfall' transfer-based workflow for improved quality of tissue microarray construction and processing in breast cancer research.Pathology oncology research : POR · 2014Article
- Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures.Cancer research · 2012Review
- Tissue microarray design and construction for scientific, industrial and diagnostic use.Journal of pathology informatics · 2012Article
- Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma.Journal of cancer research and clinical oncology · 2012Article
- Cryopreservation of viable human lung tissue for versatile post-thaw analyses and culture.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Funding
Abstract
Practice-changing evidence requires confirmation, preferably in multi-institutional clinical trials. The collection of tissue within such trials has enabled biomarker studies and evaluation of companion diagnostic tests. Tissue microarrays (TMAs) have become a standard approach in many cooperative oncology groups. A principal goal is to maximize the number of assays with this precious tissue. However, production strategies for these arrays have not been standardized, possibly decreasing the value of the study. In this article, members of the Cancer and Leukemia Group B Pathology Committee relay our experiences as array facility directors and propose guidelines regarding the production of high-quality TMAs for cooperative group studies. We also discuss statistical issues arising from having a proportion of patients available for TMAs and the possibility that patients with TMAs fail to represent the greater study population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.